Objective. Evaluation of the effectiveness of including the drug with immunostimulating and antiviral effects Groprinosin® in the combined treatment of children with hypertrophy of the pharyngeal tonsil (PHT) / chronic adenoiditis (DCA). Patients and methods. A comparative prospective study was conducted involving 355 children with PHT and DCA. 253 children received surgical treatment with the recommended basic therapy, 102 – the same, but with the addition of 2 courses of Groprinosin®. The children were observed for a year after surgery, and the frequency of episodes of acute respiratory infections (ARI) and relapses of HGM was assessed. Statistical analysis of the results was carried out using the Statistica 8 (USA) program. Results. In 81.4% of children with GGT/CA, DNA of lymphotropic herpes viruses with a significant predominance of the Epstein–Barr virus was found in the nasopharyngeal wash. In all groups after treatment, there was a statistically significant decrease in the frequency of ARI episodes: up to 2 (IQR 2–3) times a year with Groprinosin® treatment and up to 5 (IQR 2–4) without it, p = 0.023. In 29 children (8.2%) a relapse of HGM was observed: in one of the group treated with Groprinosin®, in 28 – without it. Conclusion. The high efficacy and safety of the drug Groprinosin® allows us to recommend its inclusion in the treatment protocol for children with clinically significant hypertrophy of the pharyngeal tonsil in combination with active Epstein–Barr viral infection after adenoidectomy. Key words: hypertrophy of the pharyngeal tonsil, chronic adenoiditis, treatment, relapses, inosine pranobex, children